178 related articles for article (PubMed ID: 30682092)
1. Retrospective evaluation of nitrofurantoin and pivmecillinam for the treatment of lower urinary tract infections in men.
Montelin H; Forsman KJ; Tängdén T
PLoS One; 2019; 14(1):e0211098. PubMed ID: 30682092
[TBL] [Abstract][Full Text] [Related]
2. Treatment duration of pivmecillinam in men, non-pregnant and pregnant women for community-acquired urinary tract infections caused by Escherichia coli: a retrospective Danish cohort study.
Boel JB; Jansåker F; Hertz FB; Hansen KH; Thønnings S; Frimodt-Møller N; Knudsen JD
J Antimicrob Chemother; 2019 Sep; 74(9):2767-2773. PubMed ID: 31098630
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Titelman E; Iversen A; Kalin M; Giske CG
Microb Drug Resist; 2012 Apr; 18(2):189-92. PubMed ID: 22204597
[TBL] [Abstract][Full Text] [Related]
4. Comparison of long-term, low-dose pivmecillinam and nitrofurantoin in the control of recurrent urinary tract infection in children. An open, randomized, cross-over study.
Carlsen NL; Hesselbjerg U; Glenting P
J Antimicrob Chemother; 1985 Oct; 16(4):509-17. PubMed ID: 4066562
[TBL] [Abstract][Full Text] [Related]
5. Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study.
Bollestad M; Grude N; Solhaug S; Raffelsberger N; Handal N; Nilsen HS; Romstad MR; Emmert A; Tveten Y; Søraas A; Jenum PA; Jenum S; Møller-Stray J; Weme ET; Lindbaek M; Simonsen GS;
J Antimicrob Chemother; 2018 Sep; 73(9):2503-2509. PubMed ID: 29982514
[TBL] [Abstract][Full Text] [Related]
6. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections.
Jansåker F; Frimodt-Møller N; Sjögren I; Dahl Knudsen J
J Antimicrob Chemother; 2014 Mar; 69(3):769-72. PubMed ID: 24107388
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic switch after treatment with UTI antibiotics in male patients.
Skow MAH; Vik I; Høye S
Infect Dis (Lond); 2020 Jun; 52(6):405-412. PubMed ID: 32174201
[No Abstract] [Full Text] [Related]
8. Pivmecillinam--therapy of choice for lower urinary tract infection.
Graninger W
Int J Antimicrob Agents; 2003 Oct; 22 Suppl 2():73-8. PubMed ID: 14527775
[TBL] [Abstract][Full Text] [Related]
9. Retrospective study of men with
Jansåker F; Boel JB; Frimodt-Møller N; Knudsen JD
Scand J Prim Health Care; 2020 Mar; 38(1):101-103. PubMed ID: 31997687
[No Abstract] [Full Text] [Related]
10. Different antibiotic regimes in men diagnosed with lower urinary tract infection - a retrospective register-based study.
Kornfält Isberg H; Hedin K; Melander E; Mölstad S; Cronberg O; Engström S; Lindbäck H; Neumark T; Ekman GS; Beckman A
Scand J Prim Health Care; 2020 Sep; 38(3):291-299. PubMed ID: 32686974
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP
BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687
[TBL] [Abstract][Full Text] [Related]
12. Emerging clinical role of pivmecillinam in the treatment of urinary tract infections caused by Extended Spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
Int J Clin Pract; 2019 Sep; 73(9):1-5. PubMed ID: 31243859
[TBL] [Abstract][Full Text] [Related]
13. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
J Infect Public Health; 2019; 12(6):843-846. PubMed ID: 31176606
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of pivmecillinam in oral step-down treatment in hospitalised patients with E. coli bacteremic urinary tract infection; a single-arm, uncontrolled treatment study.
Hansen BÅ; Grude N; Lindbæk M; Stenstad T
BMC Infect Dis; 2022 May; 22(1):478. PubMed ID: 35590284
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial resistance of clinical Enterobacterales isolates from urine samples, Germany, 2016 to 2021.
Stoltidis-Claus C; Rosenberger KD; Mandraka F; Quante X; Gielen J; Hoffmann D; Wisplinghoff H; Jazmati N
Euro Surveill; 2023 May; 28(19):. PubMed ID: 37166759
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of Escherichia coli causing persistence or relapse of urinary tract infections: phylogenetic groups, virulence factors and biofilm formation.
Ejrnæs K; Stegger M; Reisner A; Ferry S; Monsen T; Holm SE; Lundgren B; Frimodt-Møller N
Virulence; 2011; 2(6):528-37. PubMed ID: 22030858
[TBL] [Abstract][Full Text] [Related]
17. Nitrofurantoin in the treatment of extended-spectrum β-lactamase-producing Escherichia coli-related lower urinary tract infection.
Tasbakan MI; Pullukcu H; Sipahi OR; Yamazhan T; Ulusoy S
Int J Antimicrob Agents; 2012 Dec; 40(6):554-6. PubMed ID: 23063743
[TBL] [Abstract][Full Text] [Related]
18. Comparison of pivmecillinam and cephalexin in acute uncomplicated urinary tract infection.
Menday AP
Int J Antimicrob Agents; 2000 Jan; 13(3):183-7. PubMed ID: 10724022
[TBL] [Abstract][Full Text] [Related]
19. Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: a randomized controlled trial.
Bjerrum L; Gahrn-Hansen B; Grinsted P
Scand J Prim Health Care; 2009; 27(1):6-11. PubMed ID: 18991182
[TBL] [Abstract][Full Text] [Related]
20. Use of other antimicrobial drugs is associated with trimethoprim resistance in patients with urinary tract infections caused by E. coli.
Mulder M; Verbon A; Lous J; Goessens W; Stricker BH
Eur J Clin Microbiol Infect Dis; 2019 Dec; 38(12):2283-2290. PubMed ID: 31494829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
